Ionis Pharmaceuticals (NASDAQ:IONS) Receives Outperform Rating from William Blair

William Blair reissued their outperform rating on shares of Ionis Pharmaceuticals (NASDAQ:IONS) in a research report released on Friday morning,RTT News reports. William Blair also issued estimates for Ionis Pharmaceuticals’ FY2028 earnings at $2.07 EPS.

A number of other analysts have also recently commented on IONS. Guggenheim dropped their target price on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. Piper Sandler dropped their price objective on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. StockNews.com downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, September 26th. Finally, JPMorgan Chase & Co. raised their price objective on Ionis Pharmaceuticals from $50.00 to $55.00 and gave the company a “neutral” rating in a research report on Monday, August 26th. Two analysts have rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Ionis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $60.65.

Ionis Pharmaceuticals Trading Up 0.1 %

IONS opened at $35.63 on Friday. The company has a quick ratio of 8.82, a current ratio of 8.91 and a debt-to-equity ratio of 1.86. Ionis Pharmaceuticals has a 52 week low of $33.33 and a 52 week high of $54.44. The stock has a market cap of $5.63 billion, a PE ratio of -14.60 and a beta of 0.35. The business has a 50 day moving average of $37.44 and a 200-day moving average of $42.28.

Insider Activity

In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 6,630 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total value of $252,271.50. Following the transaction, the chief executive officer now directly owns 167,393 shares of the company’s stock, valued at approximately $6,369,303.65. This trade represents a 3.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Eric Swayze sold 1,194 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $37.92, for a total transaction of $45,276.48. Following the sale, the executive vice president now directly owns 33,713 shares of the company’s stock, valued at $1,278,396.96. The trade was a 3.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 7,877 shares of company stock valued at $299,578 over the last three months. Insiders own 2.71% of the company’s stock.

Institutional Trading of Ionis Pharmaceuticals

Several large investors have recently added to or reduced their stakes in IONS. Vanguard Personalized Indexing Management LLC boosted its stake in shares of Ionis Pharmaceuticals by 3.5% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,624 shares of the company’s stock worth $363,000 after acquiring an additional 261 shares during the last quarter. Nicollet Investment Management Inc. lifted its position in Ionis Pharmaceuticals by 1.5% during the third quarter. Nicollet Investment Management Inc. now owns 20,402 shares of the company’s stock valued at $817,000 after purchasing an additional 294 shares in the last quarter. Amalgamated Bank lifted its position in Ionis Pharmaceuticals by 3.1% during the third quarter. Amalgamated Bank now owns 9,957 shares of the company’s stock valued at $399,000 after purchasing an additional 300 shares in the last quarter. GAMMA Investing LLC increased its position in Ionis Pharmaceuticals by 83.9% in the third quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock worth $27,000 after buying an additional 303 shares in the last quarter. Finally, Itau Unibanco Holding S.A. raised its stake in shares of Ionis Pharmaceuticals by 40.9% in the third quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company’s stock worth $43,000 after buying an additional 314 shares during the period. 93.86% of the stock is currently owned by institutional investors.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.